arrow
L

Lyudmila Zhukova

sbih moscow clinical scientific and practical center named after a.s. loginov
H指数:12
被引数:1,338

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Atezolizumab plus pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer: final results of the phase III IMpassion050 trial

阿特珠单抗联合帕妥珠单抗、曲妥珠单抗和化疗治疗HER2阳性早期乳腺癌:III期IMpassion050试验的最终结果

2026-09-240
OA
Multicenter Prospective Phase II Study of Induction Therapy With Pembrolizumab, Cisplatin, and Fluorouracil in Patients With Locally Advanced Head and Neck Cancer

多中心前瞻性II期研究:采用帕博利珠单抗、顺铂和氟尿嘧啶对局部晚期头颈癌患者进行诱导治疗

2026-05-010
PRE
Real-world efficacy of lenvatinib and pembrolizumab as first-line therapy in patients with metastatic renal cell carcinoma with high burden disease

仑伐替尼和帕博利珠单抗在治疗高肿瘤负荷的转移性肾细胞癌患者中的一线治疗真实世界疗效

2024-12-010
PRE
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer

CAPItello-291研究的简明语言摘要: 激素受体阳性的晚期乳腺癌中的Capivasertib

2024-09-162
OAAI
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study

Capivasertib和fulvestrant治疗激素受体阳性晚期乳腺癌患者: III期CAPItello-291研究中常见不良事件的特征、时程和处理

2024-09-013
OAAI
The impact of inhalation versus total intravenous anesthesia on the immune status in patients undergoing breast cancer surgery: a double-blind randomized clinical trial (TeMP)
2024-07-261
OAAI
Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR positive/HER2-negative advanced breast cancer: exploratory analysis of PFS by AKT pathway gene from the Phase 3 CAPItello-291 trial
2024-05-021
PRE
Patient-reported outcomes from the Phase 3 CAPItello-291 trial investigating capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR-positive/HER2-negative advanced breast cancer
2024-05-022
PRE
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer

Capivasertib在激素受体阳性晚期乳腺癌中的应用

2023-06-01199
OA
Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial
2023-03-0121
PRE
Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07)
2023-03-012
PRE